Abstract:Two series of new pyridyl-bearing fused bicyclic analogues designed to target the dual-tolerant regions of the non-nucleoside reverse transcriptase inhibitor (NNRTI)-binding pocket were synthesized and evaluated for their anti-HIV activities. Several compounds, such as 6, 14, 15, 21, 30, and 33, were found to be potent inhibitors against the wild-type (WT) HIV-1 strain or multiple NNRTI-resistant strains at low nanomolar levels. Detailed structure–activity relationships were obtained by utilizing the variation of moieties within the corresponding pharmacophores. In vitro metabolic stability profiles and some drug-like properties of selected compounds were assessed, furnishing the preliminary structure–metabolic stability relationships. Furthermore, molecular modeling studies elucidated the binding modes of compounds 6, 15, 21, and 30 in the binding pocket of WT, E138K, K103N, or Y181C HIV-1 RTs. These promising compounds can be used as lead compounds and warrant further structural optimization to yield more active HIV-1 inhibitors.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00987.Molecular formula strings (CSV)In vitro anti-HIV assays in MT-4 cells; WT HIV-1 RT inhibition assays; metabolic stability assays in human liver microsomes; molecular modeling; predicted miLogP and MolLogP values of target compounds and controls; mean distance and standard deviation values for selected ligand–protein contacts in simulated systems; regression analysis of miLogP values and MolLogP values; rmsd profiles for the protein backbone, NNRTI-binding site, and simulated inhibitors for the RT-inhibitor complexes; time-dependent distance distribution for d1–d4 for RT-inhibitor complexes; representation of the molecular interaction potential for the interaction of compounds 6, 15, 21, and 30 with a positively and a negatively charged atom; and 1H NMR, 13C NMR, and ESI-MS spectra for the target compounds (PDF).This article has not yet been cited by other publications.

Design, synthesis, and biological activity of a novel series of 2,5-disubstituted furans/pyrroles as HIV-1 fusion inhibitors targeting gp41.

Design, Synthesis, and Biological Activity of Novel 5-((Arylfuran/1h-pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl)phenyl)thiazolidin-4-ones As HIV-1 Fusion Inhibitors Targeting Gp41.

Design, Synthesis, and Structure−Activity Relationship of a Novel Series of 2-Aryl 5-(4-Oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl)furans as HIV-1 Entry Inhibitors<sup>⊥</sup>

Small molecule fusion inhibitors: design, synthesis and biological evaluation of (Z)-3-(5-(3-benzyl-4-oxo-2-thioxothiazolidinylidene)methyl)-N-(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyrroles and related derivatives targeting HIV-1 gp41.

Design, Synthesis and Biological Evaluation of 3-Substituted 2,5-Dimethyl-n-(3-(1h-tetrazol-5-yl)phenyl)pyrroles As Novel Potential HIV-1 Gp41 Inhibitors

Design, Synthesis, and Biological Evaluation of N-Carboxyphenylpyrrole Derivatives As Potent HIV Fusion Inhibitors Targeting Gp41

N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.

ChemInform Abstract: Structure‐Based Design, Synthesis and Biological Evaluation of New N‐Carboxyphenylpyrrole Derivatives as HIV Fusion Inhibitors Targeting gp41.

N-Substituted Pyrrole Derivatives As Novel Human Immunodeficiency Virus Type 1 Entry Inhibitors That Interfere with the Gp41 Six-Helix Bundle Formation and Block Virus Fusion

Design, Synthesis, and Biological Evaluation of Highly Potent Small Molecule–Peptide Conjugates As New HIV-1 Fusion Inhibitors

Design, Synthesis and Activity Evaluation of Novel Peptide Fusion Inhibitors Targeting HIV-1 Gp41

Design and Synthesis of a New Series of Cyclopropylamino-Linking Diarylpyrimidines As HIV Non-Nucleoside Reverse Transcriptase Inhibitors.

Synthesis and Biological Evaluation of Pyridinone Analogues As Novel Potent HIV-1 NNRTIs.

Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs

Pharmacophore-fusing Design of Pyrimidine Sulfonylacetanilides As Potent Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase.

Design of Biphenyl-Substituted Diarylpyrimidines with a Cyanomethyl Linker as HIV-1 NNRTIs via a Molecular Hybridization Strategy.

Structure-based design, synthesis, and biological characterization of indolylarylsulfone derivatives as novel human immunodeficiency virus type 1 inhibitors with potent antiviral activities and favorable drug-like profiles

Disubstituted pyrimidine-5-carboxamide derivatives as novel HIV-1 NNRTIs: Crystallographic overlay-based molecular design, synthesis, and biological evaluation

Rational Design of Sulfonyl-?-AApeptides as Highly Potent HIV-1 Fusion Inhibitors with Broad-Spectrum Activity

Design of highly potent HIV fusion inhibitors based on artificial peptide sequences.

Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies